Sanofi has officially completed the acquisition of DR-0201, a novel bispecific myeloid cell engager, from Dren Bio, Inc., a private clinical-stage biopharmaceutical company. This strategic move supports Sanofi’s long-term vision to become the global leader in immunology and enhances its already robust immunology pipeline.
Following the acquisition, DR-0201 has been renamed SAR448501.
SAR448501 is a targeted bispecific myeloid cell engager designed to deplete B-cells by activating tissue-resident and trafficking myeloid cells, inducing targeted phagocytosis. It has demonstrated:
By deeply depleting B-cells, SAR448501 may reset the adaptive immune system, potentially leading to sustained, treatment-free remission in patients with refractory autoimmune conditions, such as systemic lupus erythematosus — a field with significant unmet medical needs.
Sanofi acquired the asset through the purchase of Dren 0201, Inc., a Dren Bio affiliate. The deal includes:
Following the transaction, Dren Bio will continue to operate independently, focusing on advancing its pipeline of antibody therapeutics that selectively deplete pathogenic cells and other disease-causing agents.
The acquisition of SAR448501 aligns with Sanofi’s broader goal to transform treatment paradigms in immunology by investing in innovative, high-impact therapies.
Sanofi is a global healthcare innovator driven by a singular purpose:
“We chase the miracles of science to improve people’s lives.”
Across the globe, Sanofi’s dedicated teams are working to redefine the practice of medicine, making what once seemed impossible, possible.